Abstract | BACKGROUND: Human cytomegalovirus (HCMV) is involved in complications on immunocompromised patients. Current therapeutics are associated with several drawbacks, such as nephrotoxicity. PURPOSE: STUDY DESIGN: We first selected the most efficient new synthetic chalcones for their effect against COX-2-catalyzed PGE2. STUDY SAMPLE: Among the selected compounds, we assessed the antiviral efficacy against different HCMV strains, such as the laboratory strain AD169 and clinical strains (naïve or multi-resistant to conventional drugs) and toxicity on human cells. RESULTS: CONCLUSION: These results provide a promising search path for potential bitherapies against HCMV.
|
Authors | D Andouard, R Gueye, S Hantz, C Fagnère, B Liagre, L Bernardaud, C Pouget, J L Duroux, S Alain |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 26
Issue 6-8
Pg. 117-125
(11 2021)
ISSN: 2040-2058 [Electronic] England |
PMID | 35485337
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Cyclooxygenase 2 Inhibitors
- Chalcone
- Artesunate
- Cyclooxygenase 2
- Dinoprostone
- Ganciclovir
|
Topics |
- Antiviral Agents
(pharmacology)
- Artesunate
(pharmacology)
- Chalcone
(pharmacology)
- Cyclooxygenase 2
(pharmacology)
- Cyclooxygenase 2 Inhibitors
(pharmacology)
- Cytomegalovirus
- Dinoprostone
(pharmacology)
- Ganciclovir
(pharmacology)
- Humans
|